VIM and hepatocellular carcinoma: As demonstrated in the study of Hea Ry Oh et al.,36 a co-delivery LNP system targeting the ASGPR was developed which utilized galactose-modified cationic LNP to encapsulate the doxorubicin and vimentin siRNA, forming nanoparticles with an average diameter of approximately 100 nm for synergistic hepatocellular carcinoma (HCC) therapy, achieving drug encapsulation efficiency of 80.57% with a loading efficiency (LE) of 7.46%.